HK1166978A1 - Oxadiazole derivatives and their use as metabotropic glutamate receptor - 842 potentiators 842 - Google Patents

Oxadiazole derivatives and their use as metabotropic glutamate receptor - 842 potentiators 842

Info

Publication number
HK1166978A1
HK1166978A1 HK12106999.4A HK12106999A HK1166978A1 HK 1166978 A1 HK1166978 A1 HK 1166978A1 HK 12106999 A HK12106999 A HK 12106999A HK 1166978 A1 HK1166978 A1 HK 1166978A1
Authority
HK
Hong Kong
Prior art keywords
potentiators
glutamate receptor
metabotropic glutamate
oxadiazole derivatives
oxadiazole
Prior art date
Application number
HK12106999.4A
Other languages
English (en)
Chinese (zh)
Inventor
Joshua Clayton
Ian Egle
James Empfield
James Folmer
Methvin Isaac
Fupeng Ma
Abdelmalik Slassi
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40093925&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1166978(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1166978A1 publication Critical patent/HK1166978A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
HK12106999.4A 2007-06-07 2010-09-15 Oxadiazole derivatives and their use as metabotropic glutamate receptor - 842 potentiators 842 HK1166978A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94255307P 2007-06-07 2007-06-07

Publications (1)

Publication Number Publication Date
HK1166978A1 true HK1166978A1 (en) 2012-11-16

Family

ID=40093925

Family Applications (2)

Application Number Title Priority Date Filing Date
HK10108742.2A HK1142318A1 (en) 2007-06-07 2010-09-15 Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators - 842
HK12106999.4A HK1166978A1 (en) 2007-06-07 2010-09-15 Oxadiazole derivatives and their use as metabotropic glutamate receptor - 842 potentiators 842

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK10108742.2A HK1142318A1 (en) 2007-06-07 2010-09-15 Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators - 842

Country Status (34)

Country Link
US (2) US8377940B2 (es)
EP (2) EP2444399B1 (es)
JP (2) JP5416696B2 (es)
KR (2) KR20150116907A (es)
CN (2) CN102977086B (es)
AR (1) AR066882A1 (es)
AU (1) AU2008260717B2 (es)
BR (1) BRPI0812889A2 (es)
CA (1) CA2690856C (es)
CL (1) CL2008001667A1 (es)
CO (1) CO6251287A2 (es)
CY (2) CY1113422T1 (es)
DK (2) DK2444399T3 (es)
EC (1) ECSP109856A (es)
ES (2) ES2393425T7 (es)
HK (2) HK1142318A1 (es)
HR (2) HRP20120909T4 (es)
IL (1) IL202158A (es)
ME (1) ME01488B (es)
MX (1) MX2009013078A (es)
MY (1) MY158066A (es)
NZ (1) NZ582445A (es)
PE (1) PE20090328A1 (es)
PL (2) PL2444399T3 (es)
PT (2) PT2167502E (es)
RS (2) RS53845B1 (es)
RU (2) RU2470931C2 (es)
SA (1) SA08290344B1 (es)
SI (2) SI2167502T1 (es)
TW (1) TWI417100B (es)
UA (1) UA99129C2 (es)
UY (1) UY31124A1 (es)
WO (1) WO2008150233A1 (es)
ZA (1) ZA200908285B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807706B2 (en) * 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
US7868008B2 (en) * 2005-08-12 2011-01-11 Astrazeneca Ab Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
TW200804281A (en) * 2006-02-16 2008-01-16 Astrazeneca Ab New metabotropic glutamate receptor-potentiating isoindolones
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200911255A (en) 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841
TWI417100B (zh) * 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
US9114138B2 (en) 2007-09-14 2015-08-25 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones
JP5366269B2 (ja) 2007-09-14 2013-12-11 ジャンセン ファーマシューティカルズ， インコーポレイテッド． １，３−二置換４−（アリル−ｘ−フェニル）−１ｈ−ピリジン−２−オン
CN101801930B (zh) 2007-09-14 2013-01-30 奥梅-杨森制药有限公司 1,3-二取代的-4-苯基-1h-吡啶-2-酮
US8785486B2 (en) * 2007-11-14 2014-07-22 Janssen Pharmaceuticals, Inc. Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US7790760B2 (en) * 2008-06-06 2010-09-07 Astrazeneca Ab Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286
DK2307389T3 (da) 2008-06-20 2013-04-02 Astrazeneca Ab Dibenzothiazepinderivat og anvendelser deraf
WO2010025890A1 (en) 2008-09-02 2010-03-11 Ortho-Mcneil-Janssen Pharmaceuticals, Inc 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
MX2011011962A (es) 2009-05-12 2012-02-28 Janssen Pharmaceuticals Inc Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostericos positivos de receptores de glutamato metabotropico (mglur2).
SG10201402250TA (en) 2009-05-12 2014-07-30 Janssen Pharmaceuticals Inc 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
AU2011203993A1 (en) * 2010-01-07 2012-08-02 Astrazeneca Ab Process for making a metabotropic glutamate receptor positive allosteric modulator - 874
MX2012012447A (es) * 2010-04-30 2012-11-21 Astrazeneca Ab Polimorfos de modulador alosterico positivo de receptores metabotropicos de glutamato.
ES2552879T3 (es) 2010-11-08 2015-12-02 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
WO2012062750A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
EP2643320B1 (en) 2010-11-08 2015-03-04 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CN102180872B (zh) * 2011-04-01 2014-04-02 华中科技大学 [1,3,4]噁二唑类衍生物及其应用
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
EA201891617A3 (ru) 2014-01-21 2019-04-30 Янссен Фармацевтика Нв Комбинации, содержащие положительные аллостерические модуляторы или ортостерические агонисты метаботропного глутаматергического рецептора 2 подтипа, и их применение
HUE053734T2 (hu) 2014-01-21 2021-07-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait tartalmazó kombinációk és alkalmazásuk
JP6671456B2 (ja) 2015-07-17 2020-03-25 武田薬品工業株式会社 複素環化合物
EP3327019A4 (en) * 2015-07-17 2019-04-03 Takeda Pharmaceutical Company Limited HETEROCYCLIC CONNECTION
EP3342772A4 (en) 2015-08-25 2019-03-27 Takeda Pharmaceutical Company Limited HETEROCYCLIC COMPOUND
WO2020102198A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
WO2020102216A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Substituted heterocyclic derivatives as pi3k inhibitors
WO2020102150A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
GB2621323A (en) * 2022-08-03 2024-02-14 Sirgartan Holdings Ltd Treatments for obsessive compulsive disorder

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2008803A (en) * 1932-04-18 1935-07-23 Stephan Engineering Corp Fuel atomizing and igniting means
US3993617A (en) * 1975-10-30 1976-11-23 Morton-Norwich Products, Inc. Antifungal 2-substituted phthalimidines
US5175157A (en) * 1985-11-27 1992-12-29 Boehringer Ingelheim Gmbh Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them
WO1992017448A1 (en) 1991-04-01 1992-10-15 Kyowa Hakko Kogyo Co., Ltd. 3-methyleneisoindolin-1-one derivative
TW219935B (es) 1991-12-25 1994-02-01 Mitsubishi Chemicals Co Ltd
EP0602814A1 (en) 1992-12-18 1994-06-22 Takeda Chemical Industries, Ltd. Crystal forms of optically active isoindolines and their use
RU2124511C1 (ru) * 1993-05-14 1999-01-10 Фармасьютикал Ко., Лтд Производные пиперазина
US5681954A (en) * 1993-05-14 1997-10-28 Daiichi Pharmaceutical Co., Ltd. Piperazine derivatives
WO1997029079A1 (fr) * 1996-02-06 1997-08-14 Japan Tobacco Inc. Composes chimiques et utilisation pharmaceutique
WO1998054135A1 (fr) 1997-05-30 1998-12-03 Meiji Seika Kaisha, Ltd. Composes heterocycliques azotes et medicament contre l'hyperlipemie en contenant
CA2311131A1 (en) 1997-11-21 1999-06-03 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists for treating central nervous system diseases
ES2291293T3 (es) * 2000-02-29 2008-03-01 Mitsubishi Pharma Corporation Nuevos derivados amida ciclicos.
IL153645A0 (en) 2000-07-31 2003-07-06 Smithkline Beecham Plc Carboxamide compounds and their use as antagonists of a human 11cby receptor
DE60233043D1 (de) * 2001-04-19 2009-09-03 Eisai R&D Man Co Ltd 2-iminoimidazolderivate
IL160253A0 (en) 2001-08-09 2004-07-25 Ono Pharmaceutical Co Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
WO2003087044A2 (en) 2002-04-09 2003-10-23 7Tm Pharma A/S Novel carboxamide compounds for use in mch receptor related disorders
FR2840302B1 (fr) 2002-06-03 2004-07-16 Aventis Pharma Sa Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
DE10238865A1 (de) 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB0223232D0 (en) 2002-10-07 2002-11-13 Pfizer Ltd Chemical compounds
KR101149978B1 (ko) * 2002-11-26 2012-06-01 마루이시세이야쿠가부시키가이샤 이소인돌린 유도체
CN100457731C (zh) 2003-03-26 2009-02-04 麦克公司 代谢型谷氨酸受体的苯甲酰胺调节剂
GB0308025D0 (en) 2003-04-07 2003-05-14 Glaxo Group Ltd Compounds
US7129260B2 (en) * 2003-06-02 2006-10-31 Abbott Laboratories Isoindolinone kinase inhibitors
US20070135485A1 (en) 2003-10-22 2007-06-14 Gillig James R Novel mch receptor antagonists
JP2007519754A (ja) 2004-01-30 2007-07-19 スミスクライン ビーチャム コーポレーション 化合物
CA2556320A1 (en) * 2004-02-18 2005-09-01 Astrazeneca Ab Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists for the treatment of gastrointestinal disorders
EP1726585A4 (en) 2004-03-05 2009-07-15 Banyu Pharma Co Ltd HETEROCYCLIC DERIVATIVE WITH FIVE ELEMENTS SUBSTITUTED BY A DIARYLE
EA011764B1 (ru) 2004-03-05 2009-06-30 Ниссан Кемикал Индастриз, Лтд. Изоксазолинзамещённое производное бензамида и пестицид
SE0400970D0 (sv) 2004-04-14 2004-04-14 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
TW200613272A (en) * 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
AU2005299797A1 (en) 2004-10-25 2006-05-04 Merck & Co., Inc. Heterocyclic indanone potentiators of metabotropic glutamate receptors
US7960417B2 (en) 2005-02-24 2011-06-14 Merck Sharp & Dohme Corp. Benzazole potentiators of metabotropic glutamate receptors
EA015813B1 (ru) * 2005-05-18 2011-12-30 Аддекс Фарма Са Замещенные производные оксадиазола в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов
GB0510142D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
TW200728277A (en) 2005-06-29 2007-08-01 Palau Pharma Sa Bicyclic derivatives as P38 inhibitors
WO2007021309A1 (en) * 2005-08-12 2007-02-22 Astrazeneca Ab Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
US7807706B2 (en) * 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
US7868008B2 (en) * 2005-08-12 2011-01-11 Astrazeneca Ab Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
ES2340321T3 (es) * 2005-09-27 2010-06-01 F.Hoffmann-La Roche Ag Oxadiazolilpirazolo-pirimidinas, como antagonistas de mglur2.
TW200804281A (en) 2006-02-16 2008-01-16 Astrazeneca Ab New metabotropic glutamate receptor-potentiating isoindolones
TW200911255A (en) * 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841
TWI417100B (zh) * 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途

Also Published As

Publication number Publication date
RS52526B2 (sr) 2018-06-29
SA08290344B1 (ar) 2011-10-03
JP5416696B2 (ja) 2014-02-12
ES2393425T7 (es) 2013-11-22
CN101679403A (zh) 2010-03-24
RU2009147708A (ru) 2011-07-20
MX2009013078A (es) 2010-01-15
PL2444399T3 (pl) 2015-04-30
CA2690856A1 (en) 2008-12-11
ME01488B (me) 2014-04-20
PE20090328A1 (es) 2009-04-24
AU2008260717B2 (en) 2012-01-19
RU2470931C2 (ru) 2012-12-27
CN102977086B (zh) 2015-04-01
ECSP109856A (es) 2010-02-26
EP2444399B1 (en) 2014-11-26
EP2167502A4 (en) 2011-04-06
US20080306077A1 (en) 2008-12-11
HRP20150210T1 (en) 2015-06-05
PT2167502E (pt) 2012-11-26
RS53845B1 (en) 2015-08-31
EP2167502B3 (en) 2013-07-10
EP2167502A1 (en) 2010-03-31
ZA200908285B (en) 2010-08-25
IL202158A (en) 2015-11-30
RS52526B (en) 2013-04-30
UA99129C2 (ru) 2012-07-25
IL202158A0 (en) 2010-06-16
BRPI0812889A2 (pt) 2017-05-23
HRP20120909T1 (en) 2012-12-31
CO6251287A2 (es) 2011-02-21
WO2008150233A1 (en) 2008-12-11
JP2014055164A (ja) 2014-03-27
SI2167502T1 (sl) 2012-12-31
CN102977086A (zh) 2013-03-20
TW200911254A (en) 2009-03-16
MY158066A (en) 2016-08-30
CA2690856C (en) 2015-12-15
ES2393425T3 (es) 2012-12-21
HRP20120909T4 (hr) 2013-11-08
EP2444399A1 (en) 2012-04-25
PL2167502T3 (pl) 2013-01-31
CL2008001667A1 (es) 2009-03-06
US8377940B2 (en) 2013-02-19
DK2444399T3 (en) 2015-03-02
SI2444399T1 (sl) 2015-03-31
NZ582445A (en) 2012-03-30
US8377939B2 (en) 2013-02-19
AR066882A1 (es) 2009-09-16
CY1113422T1 (el) 2016-06-22
AU2008260717A1 (en) 2008-12-11
CY1116150T1 (el) 2017-02-08
JP2010529118A (ja) 2010-08-26
HK1142318A1 (en) 2010-12-03
EP2167502B1 (en) 2012-09-19
PL2167502T6 (pl) 2013-12-31
PT2444399E (pt) 2015-03-04
RU2012141706A (ru) 2014-03-27
KR20100017640A (ko) 2010-02-16
ES2531443T3 (es) 2015-03-16
KR20150116907A (ko) 2015-10-16
JP5815644B2 (ja) 2015-11-17
CN101679403B (zh) 2013-01-02
DK2167502T3 (da) 2012-12-03
UY31124A1 (es) 2009-01-30
TWI417100B (zh) 2013-12-01
US20100267740A1 (en) 2010-10-21

Similar Documents

Publication Publication Date Title
HK1166978A1 (en) Oxadiazole derivatives and their use as metabotropic glutamate receptor - 842 potentiators 842
HK1155744A1 (en) Isoxazole derivatives and their use as metabotropic glutamate receptor potentiators
EP2167501A4 (en) OXADIAZOLE LIGANDS FROM METABOTROPIC GLUTAMATE RECEPTORS AND THEIR USE AS POTENTIALIZERS - 841
IL213168A0 (en) 1,2,4-oxadiazole derivatives and their therapeutic use
IL202826A0 (en) New compounds and their uses 708
AP2011005613A0 (en) Heteroaryls amide derivatives and their use as glucokinase activators.
EP2200613A4 (en) PINEZIN DERIVATIVES AND USES THEREOF
EP1951680A4 (en) NOVEL 2-AMINOPYRIMIDINONE DERIVATIVES AND THEIR USE
EP2124558A4 (en) SUBSTITUTED 1, 3-DIOXANES AND THEIR USE
GB0713259D0 (en) Pyrazine derivatives 954
EP2123644A4 (en) BENZOXAZEPINE DERIVATIVES AND THEIR USE
ZA201000107B (en) Pyrimidine derivatives 934
EP1991233A4 (en) Hydroxypiperidine derivatives and their use
IL201015A0 (en) New compounds and their uses 707
IL195430A0 (en) Arylsulfonamidyl tetralin derivatives and uses thereof
ZA200900960B (en) Arylpiperazine derivatives and uses thereof
ZA200810629B (en) Phenylpentadienoyl derivatives and their use as par 1 antagonists
IL196823A0 (en) Tetraarylporphine derivatives and uses thereof
IL200457A0 (en) Isoflavone derivatives and uses thereof
IL204617A0 (en) N-phenyl anthranilic acid derivatives and uses thereof
ZA200906673B (en) New compounds and their uses 707
GB0613709D0 (en) Biocyclo[2.2.1]hept-7-ylamine derivatives and their uses
SI2013191T1 (sl) 3,7-diamino-10H-fenotiazinske soli in njihova uporaba
GB0618761D0 (en) Derivatives 2
PL379610A1 (pl) Nowe S-mono- i S2,S5-dipodstawione pochodne 2,5-dimerkapto-1,3,4-tiodiazolu, sposób ich wytwarzania oraz zastosowanie

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190531